Oncologist. 2021 Feb;26 Suppl 2(Suppl 2):S5-S6. doi: 10.1002/onco.13665. Epub 2021 Jan 5.
Abemaciclib is the first CDK 4/6 inhibitor to show a significant clinical benefit when added to adjuvant endocrine therapy in patients with high‐risk, node‐positive, HR‐positive, HER2‐negative, early‐stage breast cancer, according to findings from the phase III monarchE trial.
根据 III 期 monarchE 试验的结果，阿贝西利是首个在高危、淋巴结阳性、HR 阳性、HER2 阴性、早期乳腺癌患者的辅助内分泌治疗中添加使用时显示出显著临床获益的 CDK4/6 抑制剂。
